Human MS Patients and Biomarkers IFNG-AS1 and UCHL1-AS1
In a study comparing 120 MS patients and 100 healthy controls, expressions of the long noncoding RNAs IFNG-AS1 and UCHL1-AS1 were significantly decreased in MS patients (p < 0.0001). Even after adjusting for age, IFNG-AS1 remained significantly lower in MS patients, suggesting it may serve as a potential biomarker for MS diagnosis (AUC = 0.838).
- Tags
- #Biomarkers
- Most relevant to
- —
Why it matters
These findings indicate that specific biomarkers like IFNG-AS1 could aid in the diagnosis of Multiple Sclerosis, enhancing our understanding of the disease's molecular aspects.
What this does not prove
The findings are preliminary and need further validation through functional studies to establish their clinical relevance.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 220 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Yes
- Relevant MS type
- All
- Publication date
- 2026-09-19
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Biomarkers
Original sources
- Primary evidenceDownregulation of IFNG-AS1 and UCHL1-AS1 in Peripheral Blood Cells of Multiple Sclerosis Patients: IFNG-AS1 as a Candidate Diagnostic Biomarker. ↗DOI: 10.1155/ijog/7231094
Supporting passages (9)
subjectsMETHODS: A total of 100 healthy controls and 120 MS patients with 98 relapsing-remitting (RR), 10 primary progressive (PP), and 12 secondary progressive (SP) cases were included in the blood sample collection.
sample sizeMETHODS: A total of 100 healthy controls and 120 MS patients with 98 relapsing-remitting (RR), 10 primary progressive (PP), and 12 secondary progressive (SP) cases were included in the blood sample collection.
primary endpoint metIFNG-AS1 may be considered a potential biomarker for MS diagnosis (AUC = 0.838).
research categoriesLong noncoding RNAs (lncRNAs) have been shown in recent research to have a role as prospective biomarkers that may offer data to forecast the onset and course of disease.
relevant ms typesMETHODS: A total of 100 healthy controls and 120 MS patients with 98 relapsing-remitting (RR), 10 primary progressive (PP), and 12 secondary progressive (SP) cases were included in the blood sample collection.
publication datePublication date: 2026-09-19
comparatorRESULTS: The expressions of IFNG-AS1 and UCHL1-AS1 were found to be significantly decreased (p < 0.0001) in patients compared to the control group.
findingsAfter adjustment for age using ANCOVA, IFNG-AS1 expression remained significantly lower in MS patients than in healthy controls (p < 0.0001).
limitationsHowever, these findings are preliminary and require further validation with functional studies to confirm clinical utility.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.